Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047216 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase 2 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00047216: Completed Phase 2 study, sponsored by University Health Network, Toronto.
NCT00047216 is a Phase 2 study that has completed, run by University Health Network, Toronto. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047216, a Phase 2 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer.
Interventions
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Phase | Phase 2 |
What the finished NCT00047216 record still lists
NCT00047216 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which tipifarnib is the first listed.
NCT00047216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047216 about?
NCT00047216 is a clinical study titled "Tipifarnib in Treating Patients With Recurrent Bladder Cancer". RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer.
What is the current status of trial NCT00047216?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-11.
What interventions are being tested in trial NCT00047216?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00047216?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia